Deutsche Effecten- und Wechsel- Beteiligungsges. AG
Deutsche Effecten- und Wechsel- Beteiligungsges. AG: DEWB holding NOXXON wins Pfizer as a strategic Partner
Ad hoc announcement transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
– Long term technology and licence contracts between NOXXON and Pfizer.
– Pfizer invests in NOXXON by means of a capital increase.
– DEWB share in NOXXON after conversion of bonds at approx. 61 percent.
Jena, 23. March 2006. NOXXON Pharma AG (NOXXON) today announced the
closing of a strategic alliance with Pfizer Inc. (NYSE: PFE). NOXXON will,
through the exploitation of their proprietary Spiegelmer® Technology,
develop product candidates against disease associated Targets identified by
Pfizer. Additionally Pfizer and NOXXON have signed a contract concerning
an exclusive world-wide licence for the NOXXON Spiegelmer NOX-B11. NOX-B11
is a Ghrelin binding Spiegelmer, which has shown the ability in
pre-clinical studies to curb appetite and induce weight loss and shall be
developed for the treatment of obesity. NOXXON shall receive upfront
payments as well as milestone payments from both agreements. Pfizer will,
by means of a capital increase, concurrently make an equity investment in
NOXXON.
The DEWB has converted the convertible bonds issued by NOXXON in the years
2004 and 2005 into equity. After this conversion and the capital increase
with regards to Pfizer the DEWB will hold a share of approx. 61 percent in
NOXXON.
Bertram Köhler, Member of the Management Board of DEWB, commented: ‘That
NOXXON is able to conclude its first Corporate Deal with this large
pharmaceutical company is evidence of the value of the Spiegelmer®-
technology. This alliance with Pfizer is a great basis for the future
development in the value of our investment.“
About DEWB: DEWB is a bank-independent, quoted investment company which
operates internationally. The company is based in Jena, one of the booming
high-tech regions of Germany especially in the field of optics. DEWB
focuses on optic-related technologies that will be one of the most
important technology drivers in the next years. As of Sept. 30th 2005 DEWB
has assets of approx. 68 million euros under management and investments in
appr. 15 companies. The 15.23 million bearer shares with a calculated
nominal value of one euro per share are traded on the stock exchange in
Frankfurt as well as in the Xetra system (www.dewb-vc.com; WKN 804 100 /
ISIN DE0008041005 / symbol: EFF).
About NOXXON Pharma AG the next generation aptamer company: Berlin-based
NOXXON Pharma AG develops biostable aptamers, novel substances based on
mirror image nucleic acids. These so-called Spiegelmers® (the German word
“Spiegel” means mirror) are highly specific for the pharmacologically
relevant target for which they were selected. Thanks to their structural
characteristics, Spiegelmers® are extremely resistant to degradation and
not immunogenic – a new generation of improved therapeutics.
Contact:
Mirko Wäckerle
Telephone: ++49 (0) 3641 65 21 58
Telefax: ++49 (0) 3641 65 21 57
E-Mail: ir@dewb-vc.com
(c)DGAP 23.03.2006
—————————————————————————
language: English
emitter: Deutsche Effecten- und Wechsel- Beteiligungsges. AG
Carl-Zeiß-Platz 16
07743 Jena Deutschland
phone: +49 (0)3641 65 2159
fax: +49 (0)3641 65 2157
email: ir@dewb-vc.com
WWW: www.dewb-vc.com
ISIN: DE0008041005
WKN: 804100
indexes:
stockmarkets: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Stuttgart
End of News DGAP News-Service
—————————————————————————
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden